Asciminib tablets 40mg/tablet, 60 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Myelosuppression: Serious thrombocytopenia and neutropenia events may occur. Complete blood counts are regularly monitored during treatment and managed by interrupting treatment or reducing dose.
• Pancreatic toxicity: Monitor serum lipase and amylase. Interrupt and then resume with a reduced dose or discontinue LuciAsc according to severity. Pancreatitis is assessed when elevated lipase is accompanied by abdominal symptoms.
• Blood Pressure: Monitor blood pressure and control blood pressure as clinically indicated. If Blood Pressure cannot be medically controlled, interrupt, reduce dose, or discontinue LuciAsc.
• Hypersensitivity reactions: May cause hypersensitivity reactions. Monitor the patient for signs and symptoms and initiate appropriate treatment as clinically indicated.
• Cardiovascular toxicity: Cardiovascular toxicity may occur. Monitor patients with a history of cardiovascular risk factors for cardiovascular signs and symptoms. Start appropriate treatment as clinically indicated.
• Embryo-fetal toxicity: May cause fetal harm. Inform fetuses of women of childbearing potential of the risks they may face and use effective contraception.

Medication risks

Adverse Reactions
The most common adverse reactions (≥ 20%) are upper respiratory tract infection, musculoskeletal pain, headache, fatigue, nausea, rash, and diarrhea.
The most common laboratory abnormalities (≥ 20%) are platelet count decreased, triglyceride increased, neutrophil count decreased, hemoglobin decreased, creatine kinase increased, alanine aminotransferase (ALT) increased, lipase increased, amylase increased, aspartate aminotransferase (AST) increased, uric acid increased, and lymphocyte count decreased.